Novelix Pharmaceuticals Limited has announced a significant capital raising initiative through a preferential allotment of equity shares. The board of directors, in their meeting held on December 11, 2025, approved the issuance of 25,00,000 equity shares to raise ₹15.00 crores in additional capital.

Share Allotment Details

The preferential allotment involves equity shares priced at ₹60.00 each, comprising a face value of ₹10.00 and a premium of ₹50.00 per share. The total fundraising amount aggregates to ₹15,00,00,000 through this preferential basis allocation to both promoter group members and non-promoters.

Major Investor Allocations

The allotment covers 40 investors across promoter group and non-promoter categories. The largest individual allocation goes to non-promoter Venkata Ramana Reddy Mallela with 3,30,000 shares, followed by promoter group member Pavani Vupparapalli receiving 3,25,000 shares. Other significant allocations include promoter Venkata Rama Rao Bommaraju (2,00,000 shares) and promoter Avinash Reddy Pandiri (1,20,000 shares).

The remaining investors receive allocations ranging from 15,000 to 1,00,000 shares each, distributed among both promoter group members and non-promoters. The allocation structure demonstrates a broad-based approach to capital raising while maintaining significant participation from the promoter group.

Regulatory Compliance and Approvals

The preferential allotment requires approval from shareholders in an Extraordinary General Meeting and appropriate regulatory authorities. The initiative falls under Section 42.62 of the Companies Act, 2013, and must comply with SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2018.

The company has appointed M/s. Bharat Khaniwal, Practicing Company Secretary (Membership No. ACS-29035), as the scrutinizer for conducting remote e-voting and e-voting during the EGM process.

Extraordinary General Meeting Schedule

NovelixPharmaceuticals has scheduled an Extraordinary General Meeting for Friday, January 9, 2026, at 03:30 P.M. The meeting will be conducted through Video Conferencing/Other Audio-Visual Means (OAVM) in compliance with applicable provisions of the Companies Act, 2013 and MCA General Circular No. 03/2025 dated September 22, 2025.

The cut-off date for determining eligibility to vote by electronic means has been set for Friday, January 2, 2026. This capital raising initiative represents a strategic move by Novelix Pharmaceuticals to strengthen its financial position and support future growth plans, subject to shareholder and regulatory approvals.

Key Points

• Trimurthi has closed its trading window
• A board meeting is scheduled to discuss fund-raising proposals
• The closure affects designated persons and their immediate relatives

Details

Trimurthi (ISIN: INE314I01036) has announced the closure of its trading window in compliance with regulatory requirements. This action precedes an upcoming board meeting where fund-raising proposals will be discussed.

Trading Window Closure

The trading window closure applies to all designated persons of the company and their immediate relatives. This measure is in line with the Securities and Exchange Board of India (SEBI) regulations, specifically the SEBI (Prohibition of Insider Trading) Regulations, 2015.

Upcoming Board Meeting

The board of directors is set to convene to consider and evaluate various fund-raising proposals. The exact date of the meeting has not been disclosed in the available information.

Implications

The closure of the trading window is a standard practice to prevent insider trading and ensure fair market practices. It suggests that the company is preparing for significant financial decisions that could potentially impact its stock price.

Investor Considerations

Investors and market participants should note that:

1. No trading activity by insiders will be permitted during this period
2. The outcome of the board meeting could have a material impact on the company's financial structure
3. Any decisions regarding fund-raising will be communicated to the public following the board meeting

Stakeholders are advised to await official announcements from Trimurthi for further details on the fund-raising proposals and their potential impact on the company's future operations and financial position.